Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella

Vaccine

Volumn 31, Issue 24, 2013, Pages 2667-2672

  Martinez Becerra, Francisco J ^a   Scobey, Micah ^a   Harrison, Kelly ^a   Choudhari, Shyamal P ^a   Quick, Amy M ^a   Joshi, Sangeeta B ^b   Middaugh, C Russell ^b   Picking, Wendy L ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Mouse; Parenteral; Shigella; Vaccine

Indexed keywords

BACTERIAL PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; PROTEIN IPAB; PROTEIN IPAD; SHIGELLA VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; FEASIBILITY STUDY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; LUNG INFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; TREATMENT RESPONSE; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DYSENTERY, BACILLARY; FECES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-17; LUNG DISEASES; MICE; MICE, INBRED BALB C; SHIGELLA FLEXNERI; SHIGELLA VACCINES; SPLEEN;

EID: 84878374877     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.012     Document Type: Article

References (35)

1. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5(July, 7):540-553.
2. WHO. Shigellosis. 2009 [cited; Available from: http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index6.html.
3. Mayet A., Manet G., Decam C., Morisson D., Bedubourg G., Pommier de Santi V., et al. Epidemiology of food-borne disease outbreaks in the French armed forces: a review of investigations conducted from 1999 to 2009. J Infect 2011, 63(November, 5):370-374.
4. Kerneis S., Guerin P.J., von Seidlein L., Legros D., Grais R.F. A look back at an ongoing problem: Shigella dysenteriae type 1 epidemics in refugee settings in Central Africa (1993-1995). PloS one 2009, 4(2):e4494.
5. Ehsani S., Santos J.C., Rodrigues C.D., Henriques R., Audry L., Zimmer C., et al. Hierarchies of host factor dynamics at the entry site of Shigella flexneri during host cell invasion. Infect Immun 2012 Jul, 80(7):2548-2557.
6. Luo X., Sun Q., Lan R., Wang J., Li Z., Xia S., et al. Emergence of a novel Shigella flexneri serotype 1d in China. Diagn Microbiol Infect Dis 2012, 31(July).
7. Allison G.E., Verma N.K. Serotype-converting bacteriophages and O-antigen modification in Shigella flexneri. Trends Microbiol 2000, 8(January, 1):17-23.
8. Hilbi H., Moss J.E., Hersh D., Chen Y., Arondel J., Banerjee S., et al. Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB. J Biol Chem 1998, 273(December, 49):32895-32900.
9. Zychlinsky A., Kenny B., Menard R., Prevost M.C., Holland I.B., Sansonetti P.J. IpaB mediates macrophage apoptosis induced by Shigella flexneri. Mol Microbiol 1994, 11(February, 4):619-627.
10. Fukumatsu M., Ogawa M., Arakawa S., Suzuki M., Nakayama K., Shimizu S., et al. Shigella targets epithelial tricellular junctions and uses a noncanonical clathrin-dependent endocytic pathway to spread between cells. Cell Host Microbe 2012, 11(April, 4):325-336.
11. Dean P. Functional domains and motifs of bacterial type III effector proteins and their roles in infection. FEMS Microbiol Rev 2011, 35(November, 6):1100-1125.
12. Faherty C.S., Maurelli A.T. Spa15 of Shigella flexneri is secreted through the type III secretion system and prevents staurosporine-induced apoptosis. Infect Immun 2009, 77(December, 12):5281-5290.
13. Ashida H., Ogawa M., Mimuro H., Kobayashi T., Sanada T., Sasakawa C. Shigella are versatile mucosal pathogens that circumvent the host innate immune system. Curr Opin Immunol 2011, 23(August, 4):448-455.
14. Dickenson N.E., Zhang L., Epler C.R., Adam P.R., Picking W.L., Picking W.D. Conformational changes in IpaD from Shigella flexneri upon binding bile salts provide insight into the second step of type III secretion. Biochemistry 2011, 50(January, 2):172-180.
15. Stensrud K.F., Adam P.R., La Mar C.D., Olive A.J., Lushington G.H., Sudharsan R., et al. Deoxycholate interacts with IpaD of Shigella flexneri in inducing the recruitment of IpaB to the type III secretion apparatus needle tip. J Biol Chem 2008, 283(July, 27):18646-18654.
16. Blocker A., Gounon P., Larquet E., Niebuhr K., Cabiaux V., Parsot C., et al. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J Cell Biol 1999, 147(November, 3):683-693.
17. Martinez-Becerra F.J., Kissmann J.M., Diaz-McNair J., Choudhari S.P., Quick A.M., Mellado-Sanchez G., et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun 2012, 80(March, 3):1222-1231.
18. Esposito S., Montinaro V., Groppali E., Tenconi R., Semino M., Principi N. Live attenuated intranasal influenza vaccine. Hum Vaccine Immunother 2012, 8(January, 1):76-80.
19. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PloS one 2009, 4(9):e6999.
20. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003, 77(September, 18):10078-10087.
21. Armstrong M.E., Lavelle E.C., Loscher C.E., Lynch M.A., Mills K.H. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J Infect Dis 2005, 192(November, 9):1628-1633.
22. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(August, 33-34):5937-5949.
23. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci: CMLS 2008, 65(October, 20):3231-3240.
24. Jones L.S., Peek L.J., Power J., Markham A., Yazzie B., Middaugh C.R. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005, 280(April, 14):13406-13414.
25. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(November, 10):6186-6197.
26. MacLeod M.K., McKee A.S., David A., Wang J., Mason R., Kappler J.W., et al. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci USA 2011, 108(May, 19):7914-7919.
27. Norton E.B., Lawson L.B., Mahdi Z., Freytag L.C., The Clements J.D. A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun 2012, 80(July, 7):2426-2435.
28. Mach H., Middaugh C.R., Lewis R.V. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Anal Biochem 1992, 200(January, 1):74-80.
29. Rasolofo-Razanamparany V., Cassel-Beraud A.M., Roux J., Sansonetti P.J., Phalipon A. Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity. Infect Immun 2001, 69(September, 9):5230-5234.
30. Ferreccio C., Prado V., Ojeda A., Cayyazo M., Abrego P., Guers L., et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol 1991, 134(September, 6):614-627.
31. Formal S.B., Oaks E.V., Olsen R.E., Wingfield-Eggleston M., Snoy P.J., Cogan J.P. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis 1991, 164(September, 3):533-537.
32. Oaks E.V., Turbyfill K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 2006, 24(March, 13):2290-2301.
33. Klee S.R., Tzschaschel B.D., Singh M., Falt I., Lindberg A.A., Timmis K.N., et al. Construction and characterization of genetically-marked bivalent anti-Shigella dysenteriae 1 and anti-Shigella flexneri Y live vaccine candidates. Microb Pathog 1997, 22(June, 6):363-376.
34. Jennison A.V., Roberts F., Verma N.K. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity. FEMS Immunol Med Microbiol 2006, 46(April, 3):444-451.
35. Sellge G., Magalhaes J.G., Konradt C., Fritz J.H., Salgado-Pabon W., Eberl G., et al. Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity. J Immunol 2010, 184(February, 4):2076-2085.